India is developing a new policy to support the $37 billion nutraceuticals industry, aiming to drive domestic manufacturing and global competitiveness. This initiative could help companies navigate regulatory hurdles and scale production, though strict quality compliance remains a vital monitorable for the sector.
The Indian government is moving toward a fresh framework to support the nation's rapidly growing nutraceuticals sector. The Ministry of Food Processing Industries has begun consulting with industry stakeholders, the Ministry of Health, and the Food Safety and Standards Authority of India (FSSAI) to design these new support measures. This initiative is aimed at transforming the industry—currently valued at approximately $37 billion to $38 billion—into a larger manufacturing and export hub, with projections placing the market size near $57 billion by 2030.
The core objective of this potential policy is to bridge the gap between strong domestic consumption and the need for global-scale manufacturing. Currently, the industry faces structural challenges, including the lack of a dedicated nodal ministry to oversee business development. This often leads to regulatory friction and overlap between agencies like the FSSAI and the Drugs Controller General of India (DCGI), especially for products that blur the line between food supplements and pharmaceutical formulations.
For investors and companies, the introduction of a dedicated framework—potentially modeled on existing Production Linked Incentive (PLI) schemes used in other food processing sectors—could have significant implications. A structured incentive program could help lower the cost of capital for expansion, improve research and development (R&D) capabilities, and assist in setting up better quality-testing infrastructure. Such support is crucial for companies that need to invest heavily in clinical validation and scientific research to compete in international markets.
However, the path to expansion comes with heightened regulatory scrutiny. The government has recently tightened oversight, specifically targeting companies that make misleading health claims or sell unverified formulations. For any business in this space, maintaining high safety and quality standards is no longer just an operational choice but a necessity to align with evolving government regulations. Future support is likely to be tied to clear compliance and verified scientific standards, rather than broad-based financial aid.
Industry leaders have pointed out that while financial incentives are welcome, they must be accompanied by policy clarity. Streamlined governance, where one body provides a clear mandate, is seen as essential for scaling up. As the government continues these consultations, the key developments to watch will be the official announcement of the policy structure, the eligibility criteria for any incentive programs, and the specific focus on R&D support. These factors will determine which companies are best positioned to benefit from the shift toward formal, high-quality manufacturing.